Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2018, Article ID 3250864, 14 pages
Review Article

Mesenchymal Stromal Cell Therapy for Pancreatitis: A Systematic Review

1Center of Excellence for Stem Cells and Regenerative Medicine, Zewail City of Science and Technology, 6th of October, Giza, Egypt
2Faculty of Medicine, Menoufia University, Shebin El Kom, Menoufia, Egypt
3Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt
4Department of Ophthalmology and Micro-Technology, Yokohama City University, Yokohama, Japan

Correspondence should be addressed to Nagwa El-Badri; ge.ude.yticliawez@irdablen

Received 26 October 2017; Accepted 31 December 2017; Published 18 March 2018

Academic Editor: Tullia Maraldi

Copyright © 2018 Sara M. Ahmed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Based on animal studies, adult mesenchymal stromal cells (MSCs) are promising for the treatment of pancreatitis. However, the best type of this form of cell therapy and its mechanism of action remain unclear. Methods. We searched the PubMed, Web of Science, Scopus, Google Scholar, and Clinical websites for studies using MSCs as a therapy for both acute and chronic pancreatitis published until September 2017. Results. We identified 276 publications; of these publications, 18 met our inclusion criteria. In animal studies, stem cell therapy was applied more frequently for acute pancreatitis than for chronic pancreatitis. No clinical trials were identified. MSC therapy ameliorated pancreatic inflammation in acute pancreatitis and pancreatic fibrosis in chronic pancreatitis. Bone marrow and umbilical cord MSCs were the most frequently administered cell types. Due to the substantial heterogeneity among the studies regarding the type, source, and dose of MSCs used, conducting a meta-analysis was not feasible to determine the best type of MSCs. Conclusion. The available data were insufficient for determining the best type of MSCs for the treatment of acute or chronic pancreatitis; therefore, clinical trials investigating the use of MSCs as therapy for pancreatitis are not warranted.